peptides for skin

updated

ghk-cu is the only skin peptide with a fifty-year mechanistic file. everything else on this page is a smaller bet.

ghk-cu was isolated from human plasma by Pickart in 1973 and has the deepest cosmetic peptide file on the market: a 2014 gene-expression paper reporting that it shifted 31.2% of 13,424 measured genes by 50% or more in two cell lines, three decades of collagen and angiogenesis studies, and use as a cosmetic ingredient, which needs no FDA premarket approval. afamelanotide (scenesse) became the first melanocortin agonist with an fda approval (oct 8 2019, $20,000 per implant, narrow EPP indication). almost everything else in the skin-peptide market is downstream of those two molecules plus a handful of acetyl-octapeptide topicals with sponsor-funded data.

the cosmetic core.

compounds most directly tied to skin structure, extracellular matrix signaling, and post-procedure remodeling.

  • ghk-cu (tier S) · copper-binding tripeptide isolated from human plasma by Pickart in 1973. shifted expression of 31.2% of 13,424 measured genes by 50% or more in two cell lines (Pickart, BioMed Res Int 2014). · the anchor compound in skin-peptide research. topical and injectable evidence should not be collapsed together. the molecule-specific record is the strongest in cosmetic peptides by an order of magnitude.
  • ahk-cu (tier C) · alanine-histidine-lysine copper tripeptide. follicle-stimulation focus, narrower file than ghk-cu. · the copper-peptide cousin with the most coherent follicle and dermal signaling story. molecule-specific evidence is thinner than ghk-cu. the work that exists (Trink et al, J Drugs Dermatol 2013 combination spray studies) sits in the context cosmetic marketing actually targets.
  • klow (tier A) · kpv, bpc-157, ghk-cu, and tb-500 blend used in skin and post-procedure contexts. · mechanistically broad, commercially popular, blend-specific evidence thinner than component evidence. useful as a map of compounding-clinic practice. no approved indication.
  • glow (tier A) · bpc-157, ghk-cu, and tb-500 blend. klow without kpv. · a narrower skin-and-repair blend. the rationale comes from component mechanisms. no formal clinical trial package for the blend itself.

where marketing gets louder.

evidence or safety profile more conditional than the cosmetic core.

  • melanotan-i (tier C) · alpha-msh analog. approved as afamelanotide (scenesse) by fda oct 8 2019 for erythropoietic protoporphyria. ~$20,000 per implant. · the only melanocortin agonist with an fda approval. clinuvel's EPP indication is the cleanest piece of melanotan-class regulation. off-label tanning use is a separate question the approval does not authorize.
  • melanotan-ii (tier C) · non-selective melanocortin agonist. pigment, libido, and appetite-suppression effects are documented in the published melanocortin literature. no approved indication anywhere. · biology is not the issue. safety and regulatory framing are. case reports of melanoma transformation and dysplastic-nevi changes during off-label tanning use put this compound below the copper peptides in any cosmetic-core ranking.
  • snap-8 (tier D) · acetyl octapeptide-3 (lipotec, early 2000s). snap-25 mimic. published human studies used it inside multi-ingredient patches. · the sponsor's headline wrinkle figure could not be traced to a peer-reviewed study. delivery through stratum corneum and effect size outside sponsor protocols are the bottlenecks. no independent replication on snap-8 itself exists. the independent work in this class was run on argireline, the parent molecule.
  • glutathione (tier D) · endogenous redox tripeptide. modest oral and topical skin-brightening data. · oral and topical cosmetic signal is modest. iv skin-lightening protocols carry fda and philippine fda warnings (2011 PFDA advisory cited kidney dysfunction and stevens-johnson cases). a clinical signal, not a marketing-friendly caveat.

specific-question reference.

which peptide has the strongest skin-specific evidence?

ghk-cu. fifty years of mechanistic work since Pickart's 1973 plasma isolation, a 2014 gene-expression paper reporting 31.2% of 13,424 measured genes shifted by 50% or more in two cell lines, and use as a cosmetic ingredient, which needs no FDA premarket approval. that does not make every copper peptide equivalent and it does not make every route of administration equivalent.

are glow and klow proven as blends?

no. blend-specific clinical evidence is limited. the rationale comes from component mechanisms: ghk-cu for copper and matrix biology, bpc-157 and tb-500 for repair-pathway biology, kpv for inflammation signaling in klow.

what is the melanotan safety issue?

melanocortin activation changes pigment biology. that is the intended cosmetic effect. it also drives case reports of melanoma transformation, dysplastic-nevi changes, and cardiovascular events in off-label tanning users. afamelanotide (scenesse, fda 2019) is the same class with one narrow EPP approval. mt-ii has no approved indication anywhere.

does topical peptide evidence translate to injectable use?

no. topical, intradermal, and systemic exposure are different evidence questions. the route changes both exposure and risk.

do peptides work for anti-aging skin?

the controlled evidence is small, short and mostly topical. Argireline, a different molecule from snap-8, reduced eye-area wrinkle roughness on skin replicas while placebo did not, in 60 people over 4 weeks (Wang, Am J Clin Dermatol 2013), and pal-kttks, a palmitoyl pentapeptide, beat placebo on image-analyzed wrinkles in an industry-led, 12-week split-face trial of 93 women (Robinson, Int J Cosmet Sci 2005). oral glutathione reduced wrinkles at some measured sites against placebo over 12 weeks (Weschawalit, Clin Cosmet Investig Dermatol 2017). these trials measured wrinkles over weeks, not aging itself. ghk-cu's anti-aging file is mostly mechanistic and cosmetic: a 2026 systematic review counted 18 preclinical studies and 2 randomized trials of ghk-cu alone (Mokhtar, Aesthet Surg J 2026). controlled trials of injected ghk-cu, glow or klow for skin aging: none in PubMed or ClinicalTrials.gov as of october 2026.

what the safety literature reports.

what safety split matters most?

route. topical cosmetic peptides generally sit in a different risk category than systemic or injectable use. the same molecule answered differently at each route. read the evidence route by route.

why is glutathione iv use a safety concern?

philippine fda 2011 advisory cited kidney dysfunction and stevens-johnson syndrome cases tied to iv skin-lightening protocols. that is the clinical signal that separates it from oral or topical use.

why are blend claims hard to evaluate?

because component evidence does not automatically prove the combined formula has the same outcome, dose-response, or safety profile.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.